WILMINGTON, Delaware, March 17 -- AstraZeneca, a biopharmaceutical company, issued the following news release: * * * Eneboparatide met primary endpoint of normalizing serum calcium in adults with hypoparathyroidism at 24 weeks in CALYPSO Phase III trial Trial continues as planned to 52 weeks to further characterize the risk-benefit profile High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, more PR